Evidence map›Paper›PMID 34321484›Full record

ArticleNature communications2021

Cardiac-specific deletion of voltage dependent anion channel 2 leads to dilated cardiomyopathy by altering calcium homeostasis.

Thirupura S Shankar, Dinesh K A Ramadurai, Kira Steinhorst, Salah Sommakia, Rachit Badolia, Aspasia Thodou Krokidi, Dallen Calder, Sutip Navankasattusas, Paulina Sander, Oh Sung Kwon and 14 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Zebrafish in Cardiovascular Disease Research: from Model to Application.International journal of biological sciences · 2026
    Review
  11. Article
  12. Review
  13. Novel Drug Targets in Diastolic Heart Disease.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Thirupura S ShankarNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-5009-2770
Dinesh K A RamaduraiNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Kira SteinhorstWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, Munich, Germany.
Salah SommakiaNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Rachit BadoliaNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Aspasia Thodou KrokidiNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Dallen CalderNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Sutip NavankasattusasNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Paulina SanderWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, Munich, Germany.ORCID 0000-0002-2384-3954
Oh Sung KwonDepartment of Kinesiology, University of Connecticut, Storrs, CT, USA.
Aishwarya AravamudhanNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Jing LingNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Andreas DendorferWalter-Brendel-Center of Experimental Medicine, Ludwig-Maximilians Universität Munich, Munich, Germany.ORCID 0000-0002-7806-312X
Changmin XieDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA, USA.
Ohyun KwonDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA, USA.ORCID 0000-0002-5405-3971
Emily H Y ChengMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Kevin J WhiteheadDivision of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Thomas GudermannWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, Munich, Germany.
Russel S RichardsonGeriatric Research, Education, and Clinical Center, Salt Lake City VA Medical Center, Salt Lake City, UT, USA.
Frank B SachseNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Johann SchredelsekerWalther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, Munich, Germany.ORCID 0000-0002-6657-0466
Kenneth W SpitzerNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.
Dipayan ChaudhuriNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-0605-7334
Stavros G DrakosNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA. Stavros.Drakos@hsc.utah.edu.ORCID 0000-0002-1223-327X
University of Utah · USGerman Centre for Cardiovascular Research · DELudwig-Maximilians-Universität München · DEUniversity of Connecticut · USLake City VA Medical Center · USMemorial Sloan Kettering Cancer Center · USSouthern Utah University · USUniversity of California, Los Angeles · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
TRAINING IN CARDIOVASCULAR RESEARCHT32HL007576 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos, Robin M Shaw · 1985 to 2026
$10.6M
Phosphine-Catalyzed Annulations and Their ApplicationsR01GM071779 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OHYUN KWON · 2006 to 2026
$5.7M
Metabolic Impact and Mechanism of Enhanced Mitochondrial Calcium Uptake in Mitochondrial CardiomyopathiesR01HL141353 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Dipayan Chaudhuri · 2018 to 2026
$4.3M
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in CancerR01CA252658 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHENG, EMILY H · 2021 to 2025
$2.5M
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart FailureR01HL135121 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE · 2017 to 2021
$1.9M
Cellular Remodeling in Heart Failure and after LVAD UnloadingR01HL132067 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE, SACHSE, FRANK BERND · 2017 to 2020
$1.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA252658NHLBI NIH HHS R01 HL132067NHLBI NIH HHS R01 HL135121NHLBI NIH HHS R01 HL141353NHLBI NIH HHS T32 HL007576NIGMS NIH HHS R01 GM071779
6 · The paper itself

Abstract

Voltage dependent anion channel 2 (VDAC2) is an outer mitochondrial membrane porin known to play a significant role in apoptosis and calcium signaling. Abnormalities in calcium homeostasis often leads to electrical and contractile dysfunction and can cause dilated cardiomyopathy and heart failure. However, the specific role of VDAC2 in intracellular calcium dynamics and cardiac function is not well understood. To elucidate the role of VDAC2 in calcium homeostasis, we generated a cardiac ventricular myocyte-specific developmental deletion of Vdac2 in mice. Our results indicate that loss of VDAC2 in the myocardium causes severe impairment in excitation-contraction coupling by altering both intracellular and mitochondrial calcium signaling. We also observed adverse cardiac remodeling which progressed to severe cardiomyopathy and death. Reintroduction of VDAC2 in 6-week-old knock-out mice partially rescued the cardiomyopathy phenotype. Activation of VDAC2 by efsevin increased cardiac contractile force in a mouse model of pressure-overload induced heart failure. In conclusion, our findings demonstrate that VDAC2 plays a crucial role in cardiac function by influencing cellular calcium signaling. Through this unique role in cellular calcium dynamics and excitation-contraction coupling VDAC2 emerges as a plausible therapeutic target for heart failure.

Indexed as

HomeostasisAnimalsApoptosisCalciumCalcium SignalingCardiomyopathy, DilatedHeart FailureMiceMice, KnockoutMitochondriaMitochondrial MembranesMyocardial ContractionMyocytes, CardiacTranscriptomeVoltage-Dependent Anion Channel 2CalciumVdac2 protein, mouseVoltage-Dependent Anion Channel 2

Identifiers

PMID34321484
PMCPMC8319341
OpenAlexW3183630488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.